Dextroamphetamine - Amphetamine ER - Contract Award

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DLA TROOP SUPPORT

Contract Value

Not provided

Codes & Classification
Solicitation Number

SPE2D2-26-D-0005

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

None

Place of Performance

Indiana, UNITED STATES

SourceSAM
Documents1
The Defense Logistics Agency (DLA) Troop Support, operating under the Department of Defense, has issued an award notice for the procurement of Dextroamphetamine-Amphetamine Extended Release (ER) under contract number SPE2D2-26-D-0005. This contract is classified under NAICS code 325412, which pertains to Pharmaceutical Preparation Manufacturing, and is further identified by Product Service Code 6505, indicating its focus on pharmaceuticals. The primary objective of this procurement is to ensure a reliable supply of Dextroamphetamine-Amphetamine ER, a critical pharmaceutical product, to support the operational and medical needs of the Department of Defense. The scope of the contract encompasses the manufacturing and delivery of this medication, with the place of performance specified as Indiana, United States. The intended outcome is to maintain consistent availability of this essential medication for authorized users, thereby supporting the health and readiness of military personnel and associated beneficiaries. Key requirements for this contract include adherence to all applicable federal regulations governing pharmaceutical manufacturing, quality assurance, and supply chain integrity. The contractor is expected to deliver Dextroamphetamine-Amphetamine ER in accordance with the specifications and quantities outlined in the award documentation. Compliance with stringent quality standards and timely fulfillment of delivery schedules are critical deliverables under this contract. The contracting activity is managed by DLA Troop Support, a federal office within the Defense Logistics Agency. For further information or contract administration matters, the primary point of contact is Nancy Fernandez, who can be reached at [email protected] or by phone at 445-737-0713. A secondary contact is Jason C. Wray, available at [email protected] or (445) 737-6304. This award notice is currently active and was posted on January 15, 2026. Contractors interested in reviewing the official award documentation or seeking additional details can access the notice via the SAM.gov portal using Opportunity ID 5c2887bb6d364c1385adf66544e0df28. No specific set-aside requirements or special considerations are indicated in the available information. The contract is expected to maintain consistent requirements and objectives throughout its lifecycle, focusing on the sustained provision of high-quality pharmaceutical products to meet the needs of the Department of Defense.